Trial Profile
A Phase 2, Open-Label Extension, Efficacy and Safety Study of a Retinoic Acid Receptor Gamma (RARγ) Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs Palovarotene (Primary)
- Indications Fibrodysplasia ossificans progressiva
- Focus Therapeutic Use
- Sponsors Clementia Pharmaceuticals
- 11 Oct 2022 Status changed from suspended to completed.
- 16 Sep 2021 Planned End Date changed from 31 Oct 2021 to 31 Oct 2022.
- 16 Sep 2021 Planned primary completion date changed from 31 Oct 2021 to 31 Oct 2022.